Awakn intends to run a Phase III trial for ‘Ketamine-Assisted Psychotherapy for Alcohol Use Disorder’ Awakn announced today an exclusive license to use and deliver the ‘Ketamine in the Reduction…

Awakn announces today the publication of results from its CMO Dr. Ben Sessa’s Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential…

Today Awakn announces the appointment of James Collins as Chief Operating Officer, effective January 2021. Collins joins from Accenture Strategy where he was a Managing Director (London) for several years,…

Awakn announces today the appointment of Dr. Shaun McNulty, formerly at GlaxoSmithKline (GSK), as Chief Science Officer and Prof. Celia Morgan, from Exeter University, as Head of Ketamine-Assisted Psychotherapy for…

PRA Health Sciences selected for the study which will position Awakn at the Forefront of Psychedelic Research for Addiction Treatment Awakn announces today the selection of contract research organization (‘CRO’),…

1169082 B.C. Ltd. is pleased to announce that it has entered into a non-binding letter of intent with Awakn Life Sciences Inc., whereby 1169082 B.C. Ltd. and Awakn have agreed…

The appointment continues to strengthen Awakn’s industry leading Scientific Advisory Board Awakn is pleased to announce the appointment of Professor Celia Morgan to its Scientific Advisory Board (SAB). Celia Morgan…

Appointment of two leaders from the Multidisciplinary Association of Psychedelic Studies further strengthens AWAKN’s industry leading scientific advisory team Awakn is pleased to announce the appointment of Dr. Michael Mithoefer…

Professor of Psychiatry and Behavioural Sciences at Johns Hopkins Appointed as Member of Scientific Advisory Board Awkan is pleased to announce the appointment of Dr. Matthew Johnson, Ph.D, to its…

Science-led Drugs Charity Invites AWAKN to Join Its Working Group on Psychedelics Awakn announces today the new partnership to coincide with Drug Science’s inaugural Psychedelics Working Group meeting that took…

Former UK Government Drug TSAR Appointed as Chairman of Scientific Advisory Board Awakn is pleased to announce the appointment of Professor David Nutt as Chairman of its newly formed Scientific…

Awakn to acquire controlling interest in Dr. Ben Sessa’s clinical operations Awakn announces today that it has signed a binding investment agreement to acquire a controlling interest in Mandala Therapy…